107 related articles for article (PubMed ID: 34965954)
21. Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy.
Moisuc DC; Constantinescu D; Marinca MV; Gafton B; Pavel-Tanasa M; Cianga P
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254874
[TBL] [Abstract][Full Text] [Related]
22. Biotherapy in the Adjuvant Treatment of Colorectal Cancer.
Tazi EM; Essadi I; Boutayeb S; M'rabti H; Errihani H
Gastroenterology Res; 2011 Aug; 4(4):162-167. PubMed ID: 27942334
[TBL] [Abstract][Full Text] [Related]
23. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
Yazdani A; Lenz HJ; Pillonetto G; Mendez-Giraldez R; Yazdani A; Sanof H; Hadi R; Samiei E; Venook AP; Ratain MJ; Rashid N; Vincent BG; Qu X; Wen Y; Kosorok M; Symmans WF; Shen JPYC; Lee MS; Kopetz S; Nixon AB; Bertagnolli MM; Perou CM; Innocenti F
Res Sq; 2023 Dec; ():. PubMed ID: 38168324
[TBL] [Abstract][Full Text] [Related]
24. Pre-Surgery Inflammatory and Angiogenesis Biomarkers as Predictors of 12-Month Cancer-Related Distress: Results from the ColoCare Study.
Lindley CL; Gigic B; Peoples AR; Han CJ; Lin T; Himbert C; Warby CA; Boehm J; Hardikar S; Ashworth A; Schneider M; Ulrich A; Schrotz-King P; Figueiredo JC; Li CI; Shibata D; Siegel EM; Toriola AT; Ulrich CM; Syrjala KL; Ose J
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):363-370. PubMed ID: 36595657
[TBL] [Abstract][Full Text] [Related]
25. Personalized medicine in biomarker identification at their optimal cut-off selection.
Lewandowski TJ
Prz Gastroenterol; 2023; 18(4):402-408. PubMed ID: 38572461
[TBL] [Abstract][Full Text] [Related]
26. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies.
Yazdani A; Yazdani A; Mendez-Giraldez R; Pillonetto G; Samiei E; Hadi R; Lenz HJ; Venook A; Samiei A; Nixon A; Lucci J; Kopetz S; Bertagnolli M; Perou C; Innocenti F
Res Sq; 2024 Mar; ():. PubMed ID: 38559223
[TBL] [Abstract][Full Text] [Related]
27. Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review.
Rodriguez-Pascual J; Cubillo A
Curr Pharmacogenomics Person Med; 2017 Dec; 15(2):81-85. PubMed ID: 29657584
[TBL] [Abstract][Full Text] [Related]
28. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.
Goldberg RM; Meropol NJ; Tabernero J
Gastrointest Cancer Res; 2009 Sep; 3(5 Supplement 2):S23-7. PubMed ID: 20011561
[TBL] [Abstract][Full Text] [Related]
29. Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis.
Cui Y; Guo Y
Int J Clin Pharm; 2024 Apr; 46(2):555-557. PubMed ID: 38270779
[No Abstract] [Full Text] [Related]
30. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Nixon AB; Liu Y; Yang Q; Luo B; Starr MD; Brady JC; Kelly WK; Beltran H; Morris MJ; George DJ; Armstrong AJ; Halabi S
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347114
[TBL] [Abstract][Full Text] [Related]
32. Colon-targeted S100A8/A9-specific peptide systems ameliorate colitis and colitis-associated colorectal cancer in mouse models.
Cho E; Mun SJ; Kim HK; Ham YS; Gil WJ; Yang CS
Acta Pharmacol Sin; 2024 Mar; 45(3):581-593. PubMed ID: 38040838
[TBL] [Abstract][Full Text] [Related]
33. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
Yuki S; Yamazaki K; Sunakawa Y; Taniguchi H; Bando H; Shiozawa M; Nishina T; Yasui H; Kagawa Y; Takahashi N; Denda T; Esaki T; Kawakami H; Satake H; Takashima A; Matsuhashi N; Kato T; Asano C; Abe Y; Nomura S; Yoshino T
Cancer Med; 2023 Sep; 12(18):18702-18716. PubMed ID: 37641470
[TBL] [Abstract][Full Text] [Related]
34. Targeting angiogenesis in oncology, ophthalmology and beyond.
Cao Y; Langer R; Ferrara N
Nat Rev Drug Discov; 2023 Jun; 22(6):476-495. PubMed ID: 37041221
[TBL] [Abstract][Full Text] [Related]
35. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
Atzori MG; Ceci C; Ruffini F; Scimeca M; Cicconi R; Mattei M; Lacal PM; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428669
[TBL] [Abstract][Full Text] [Related]
36. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
[TBL] [Abstract][Full Text] [Related]
37. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
38. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
39. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
40. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
